Skip to main content
Hiv Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, China, UK, Canada - Size and Forecast 2024-2028

Hiv Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, China, UK, Canada - Size and Forecast 2024-2028

Published: Jul 2024 164 Pages SKU: IRTNTR75747

Market Overview at a Glance

$9.99 B
Market Opportunity
5.02%
CAGR
4.69
YoY growth 2023-2024(%)

HIV Drugs Market Size 2024-2028

The hiv drugs market size is forecast to increase by USD 9.99 billion at a CAGR of 5.02% between 2023 and 2028.

  • The market is experiencing significant growth due to several key factors. The increasing prevalence of HIV AIDS worldwide continues to drive market expansion. According to the World Health Organization, there were approximately 38 million people living with HIV in 2019. Moreover, expanding access to HIV treatment is another major growth factor. With advancements in HIV treatment, more individuals are able to access life-saving medications. However, drug resistance among individuals poses a significant challenge to the market. As HIV strains become resistant to current treatments, the development of new and effective drugs is crucial. This report provides a comprehensive analysis of these trends and challenges, offering insights into the future growth prospects of the market.

    • What will be the Size of the HIV Drugs Market During the Forecast Period?

    HIV Drugs Market Size

     Request Free Sample

  • The market encompasses a range of pharmaceutical products designed to manage and suppress the viral infection caused by Human Immunodeficiency Virus (HIV). This market has experienced significant growth due to the increasing prevalence of HIV and the ongoing development of new, more effective medications. Notable classes of HIV drugs include those containing CD4 modulators, such as Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, Descovy, Dovato, Emtriva, Epivir, and Epzicom. New product launches continue to drive market expansion, with companies investing in research and development to improve treatment outcomes and patient compliance. The healthcare products industry plays a crucial role In the import and export of HIV medications, ensuring access to these essential treatments for patients worldwide.
  • HIV testing procedures remain a critical aspect of disease management and prevention efforts, further fueling demand for HIV medications withIn the market.

    • How is this HIV Drugs Industry segmented and which is the largest segment?

    The hiv drugs industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

    • Distribution Channel
      • Offline
      • Online
    • Therapy
      • Combination HIV medicines
      • Integrase inhibitors
      • Non-nucleoside reverse transcriptase inhibitors
      • Others
    • Geography
      • North America
        • Canada
        • US
      • Europe
        • Germany
        • UK
      • Asia
        • China
      • Rest of World (ROW)

      By Distribution Channel Insights

      • The offline segment is estimated to witness significant growth during the forecast period.

      Offline distribution channels, including pharmacies, drugstores, hospitals, and clinics, remain a significant segment In the market. Pharmacies and drugstores serve as crucial points of sale for HIV medications, particularly antiretroviral therapy (ART), which is essential for managing HIV/AIDS. The offline distribution segment caters to various patient populations, including those in regions with limited internet access or who prefer face-to-face interactions with healthcare professionals. Key HIV drugs, such as Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, Descovy, Dovato, Emtriva, Epivir, Epzicom, Truvada, Biktavir, Edurant, Aptivus, Kaletra, Lexiva, Norvir, Viracept, Selzentry, Fuzeon, Rukobia, Isentress, Tivicay, Apretude, and Juluca, are distributed offline through these channels.

      The offline distribution segment's growth is influenced by factors like the prevalence of HIV, testing procedures, and the availability of various HIV medications. Import and export regulations, as well as the increasing demand for healthcare products, further impact this market.

      HIV Drugs Market Size

      Get a glance at the  HIV Drugs Industry report of share of various segments Request Free Sample

      The Offline segment was valued at USD 25.82 billion in 2018 and showed a gradual increase during the forecast period.

      Regional Analysis

      • North America is estimated to contribute 49% to the growth of the global market during the forecast period.

      Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

      HIV Drugs Market Share by Geography

      For more insights on the market share of various regions, Request Free Sample

      The North American the market has experienced substantial growth due to advancements in medical research, enhanced healthcare infrastructure, and heightened awareness about HIV/AIDS. With a significant patient population and established healthcare systems In the United States, Canada, and Mexico, North America is a leading market for HIV drugs. Key trends include the development of combination HIV medicines, such as Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, Descovy, Dovato, Emtriva, Epivir, Epzicom, Truvada, Biktavir, Edurant, Aptivus, Kaletra, Lexiva, Norvir, Viracept, Selzentry, Fuzeon, Rukobia, Isentress, Tivicay, Apretude, and Juluca. Government initiatives and partnerships with private organizations have bolstered market growth. HIV drugs, including Efavirenz tablets, fall into various classes, including integrase inhibitors, protease inhibitors (PIs), fusion inhibitors, CCR5 antagonists, and post-attachment inhibitors, as well as pharmacokinetic enhancers.

      Hospital pharmacies, drug stores, retail pharmacies, and online pharmacies distribute these essential healthcare products.

      Market Dynamics

      Our  researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

      What are the key market drivers leading to the rise In the adoption of HIV Drugs Industry?

      Increasing prevalence of HIV AIDS worldwide is the key driver of the market.

    • The market is driven by the escalating prevalence of HIV, a viral infection that attacks and weakens the immune system, leading to acquired immunodeficiency syndrome (AIDS). The global HIV infection rate continues to rise, necessitating the development and availability of effective treatment options. High-risk populations, including men who have sex with men (MSM), intravenous drug users, and sex workers, are disproportionately affected, increasing the demand for HIV medications. Combination HIV medicines, such as Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, Descovy, Dovato, Emtriva, Epivir, Epzicom, Truvada, Biktavir, Edurant, Aptivus, Kaletra, Lexiva, Norvir, Viracept, Selzentry, Fuzeon, Rukobia, Isentress, Tivicay, Apretude, and Juluca, are used to manage HIV infection.
    • These drugs belong to various classes, including integrase inhibitors, protease inhibitors (PIs), fusion inhibitors, CCR5 antagonists, post-attachment inhibitors, and pharmacokinetic enhancers. HIV drugs are available at various outlets, including hospital pharmacies, drug stores, retail pharmacies, and online pharmacies. The market for these healthcare products is dynamic, with new product launches and advancements in technology driving growth. Import and export regulations play a crucial role In the market's supply chain, ensuring the availability of these essential medications to patients worldwide. The increasing prevalence of HIV necessitates ongoing research and development to create more effective and accessible HIV drugs. The demand for these medications is expected to remain high as the global fight against HIV continues.

      • What are the market trends shaping the HIV Drugs Industry?

      Expanding access to HIV treatment is the upcoming market trend.

    • The market has witnessed notable advancements in recent years due to the increasing prevalence of HIV and the trend towards expanding access to life-saving antiretroviral therapy (ART). HIV medications, including CD 4 cells boosters like Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, Descovy, Dovato, Emtriva, Epivir, Epzicom, Truvada, Biktavir, Edurant, Aptivus, Kaletra, Lexiva, Norvir, Viracept, Selzentry, Fuzeon, Rukobia, Isentress, Tivicay, and Apretude, have become essential components of HIV treatment regimens. These drugs belong to various classes, such as integrase inhibitors, protease inhibitors (PIs), fusion inhibitors, CCR5 antagonists, post-attachment inhibitors, and pharmacokinetic enhancers. Hospital pharmacies, drug stores, retail pharmacies, and online pharmacies play a crucial role In the distribution of these HIV drugs.
    • The market dynamics are influenced by factors such as new product launches, import and export regulations, and healthcare policies. For instance, the production and distribution of generic versions of HIV drugs have significantly contributed to expanding access to treatment, particularly in low- and middle-income countries. Additionally, increased funding and resources from governments, international organizations, and NGOs have improved healthcare systems and infrastructure, ensuring that more people living with HIV have access to ART. Testing procedures for HIV infection are also a critical aspect of the market. Early diagnosis and timely initiation of treatment are essential for effective disease management and reducing the risk of transmission.
    • The availability of HIV medications and testing procedures has led to a growing patient population, further driving market growth. In conclusion, the market is a dynamic and evolving industry, driven by the increasing prevalence of HIV, the trend towards expanding access to treatment, and advancements in drug development. The market is expected to continue growing as new treatments and delivery methods are developed and made available to patients.

      • What challenges does the HIV Drugs Industry face during its growth?

      Drug resistance among individuals is a key challenge affecting the industry growth.

    • The market faces a substantial challenge with the development of drug-resistant strains of the human immunodeficiency virus (HIV). HIV's high mutation rate allows it to evade antiretroviral therapy (ART), leading to treatment failure. This occurs when individuals with HIV do not strictly adhere to their prescribed treatment regimen or receive insufficient drug potency, enabling the virus to mutate and resist the drugs. The prevalence of HIV and the need for effective HIV medications continue to grow, with new product launches In the market. These include combination HIV medicines like Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, Descovy, Dovato, Emtriva, Epivir, Epzicom, Truvada, Biktavir, Edurant, Aptivus, Kaletra, Lexiva, Norvir, Viracept, Selzentry, Fuzeon, Rukobia, Isentress, Tivicay, Apretude, and Juluca.
    • HIV medications are available through various channels, including hospital pharmacies, drug stores, retail pharmacies, and online pharmacies. These medications fall into different drug classes, such as integrase inhibitors, protease inhibitors (PIs), fusion inhibitors, CCR5 antagonists, and post-attachment inhibitors. Pharmacokinetic enhancers are also used to improve the effectiveness of these drugs. Drug resistance poses a significant challenge to The market, as it can lead to treatment failure and the need for more expensive and complex treatment regimens. Adherence to treatment plans and ensuring adequate drug potency are crucial in preventing the development of drug-resistant strains. The ongoing research and development of new HIV medications aim to address this challenge and improve patient outcomes.

      • Exclusive Customer Landscape

      The hiv drugs market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the hiv drugs market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

      HIV Drugs Market Share by Geography

       Customer Landscape

      Key Companies & Market Insights

      Companies are implementing various strategies, such as strategic alliances, hiv drugs market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.

      AbbVie Inc. - The company specializes in providing a range of HIV drugs, including Kaletra and Aluvia, to address the global demand for effective treatments against the virus. These antiretroviral therapies play a crucial role in managing HIV infection and improving patient outcomes. With a focus on innovation and accessibility, the company is dedicated to contributing to the ongoing efforts to combat HIV/AIDS and improve the lives of those affected by the disease.

      The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

      • AbbVie Inc.
      • Aspen Pharmacare Holdings Ltd.
      • Aurobindo Pharma Ltd.
      • Boehringer Ingelheim International GmbH
      • Bristol Myers Squibb Co.
      • Cadila Pharmaceuticals Ltd.
      • Cipla Inc.
      • Emcure Pharmaceuticals Ltd.
      • Gilead Sciences Inc.
      • GlaxoSmithKline Plc
      • Hetero Labs Ltd.
      • Johnson and Johnson Services Inc.
      • Lupin Ltd.
      • Macleods Pharmaceuticals Ltd.
      • Merck and Co. Inc.
      • Strides Pharma Science Ltd.
      • Sun Pharmaceutical Industries Ltd.
      • Teva Pharmaceutical Industries Ltd.
      • Torrent Pharmaceuticals Ltd.
      • Viatris Inc.

      Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

      Research Analyst Overview

      The market encompasses a diverse range of pharmaceutical products designed to manage and suppress the progression of Human Immunodeficiency Virus (HIV) infection. These medications play a crucial role in improving the quality of life for those diagnosed with HIV and reducing the transmission of the virus. HIV drugs can be categorized into various classes based on their mechanism of action. Combination HIV medicines, which consist of multiple drugs from different classes, are a common treatment approach due to their ability to suppress the virus more effectively than a single drug. Integrase inhibitors, protease inhibitors (PIs), fusion inhibitors, CCR5 antagonists, post-attachment inhibitors, and pharmacokinetic enhancers are among the primary classes of HIV drugs.

      Integrase inhibitors prevent the viral DNA from integrating into the host's DNA, while protease inhibitors block the action of the HIV protease enzyme, preventing the virus from replicating. Fusion inhibitors prevent the virus from entering the host cell, CCR5 antagonists block the action of a specific receptor on the surface of immune cells, and post-attachment inhibitors prevent the virus from uncoating once it has entered the cell. Pharmacokinetic enhancers improve the bioavailability and effectiveness of other HIV drugs. The patient population for HIV drugs is significant, with a growing number of individuals diagnosed with HIV each year. The prevalence of HIV continues to be a concern, with new cases reported globally.

      The need for effective HIV medications is, therefore, a pressing requirement. The market is characterized by continuous innovation and new product launches. Pharmaceutical companies invest heavily in research and development to bring new and improved HIV drugs to market. The import and export of HIV drugs also play a vital role in ensuring access to these life-saving medications for patients worldwide. HIV drugs are available through various channels, including hospital pharmacies, drug stores, retail pharmacies, and online pharmacies. The choice of distribution channel depends on various factors, including patient preference, accessibility, and convenience. The market is a dynamic and complex ecosystem, with various stakeholders, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies, all playing essential roles.

      The market is subject to various market forces, including regulatory requirements, pricing pressures, and competition. In conclusion, the market is a critical sector In the healthcare products industry, with a significant impact on public health. The ongoing innovation and new product launches reflect the commitment of pharmaceutical companies to improving the lives of those diagnosed with HIV. The market's complexity and dynamic nature require a nuanced understanding of various market forces and stakeholders.

      Market Scope

      Report Coverage

      Details

      Page number

      164

      Base year

      2023

      Historic period

      		 2018-2022

      Forecast period

      2024-2028

      Growth momentum & CAGR

      Accelerate at a CAGR of 5.02%

      Market growth 2024-2028

      USD 9.99 billion

      Market structure

      Fragmented

      YoY growth 2023-2024(%)

      4.69

      Key countries

      US, Germany, China, UK, and Canada

      Competitive landscape

      Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

      Request Free Sample

      What are the Key Data Covered in this HIV Drugs Market Research and Growth Report?

      • CAGR of the HIV Drugs industry during the forecast period
      • Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
      • Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
      • Accurate predictions about upcoming growth and trends and changes in consumer behaviour
      • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
      • Thorough analysis of the market’s competitive landscape and detailed information about companies
      • Comprehensive analysis of factors that will challenge the hiv drugs market growth of industry companies

      We can help! Our analysts can customize this hiv drugs market research report to meet your requirements.

      Get in touch

       

      Table of Contents not available.

      Research Methodology

      Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

      INFORMATION SOURCES

      Primary sources

      • Manufacturers and suppliers
      • Channel partners
      • Industry experts
      • Strategic decision makers

      Secondary sources

      • Industry journals and periodicals
      • Government data
      • Financial reports of key industry players
      • Historical data
      • Press releases

      DATA ANALYSIS

      Data Synthesis

      • Collation of data
      • Estimation of key figures
      • Analysis of derived insights

      Data Validation

      • Triangulation with data models
      • Reference against proprietary databases
      • Corroboration with industry experts

      REPORT WRITING

      Qualitative

      • Market drivers
      • Market challenges
      • Market trends
      • Five forces analysis

      Quantitative

      • Market size and forecast
      • Market segmentation
      • Geographical insights
      • Competitive landscape

      Interested in this report?

      Get your sample now to see our research methodology and insights!

      Download Now

      Frequently Asked Questions

      HIV Drugs market growth will increase by $ 9.99 bn during 2024-2028.

      The HIV Drugs market is expected to grow at a CAGR of 5.02% during 2024-2028.

      HIV Drugs market is segmented by Distribution Channel( Offline, Online) Therapy( Combination HIV medicines, Integrase inhibitors, Non-nucleoside reverse transcriptase inhibitors, Others)

      AbbVie Inc., Aspen Pharmacare Holdings Ltd., Aurobindo Pharma Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., Cipla Inc., Emcure Pharmaceuticals Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Labs Ltd., Johnson and Johnson Services Inc., Lupin Ltd., Macleods Pharmaceuticals Ltd., Merck and Co. Inc., Strides Pharma Science Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc. are a few of the key vendors in the HIV Drugs market.

      North America will register the highest growth rate of 49% among the other regions. Therefore, the HIV Drugs market in North America is expected to garner significant business opportunities for the vendors during the forecast period.

      US, Germany, China, UK, Canada

      • Increasing prevalence of HIV AIDS worldwideOne of the key drivers of the global HIV drugs market is the increasing prevalence of HIV worldwide. HIV is a viral infection that weakens the immune system is the driving factor this market.
      • leading to acquired immunodeficiency syndrome (AIDS). Here are some reasons why increasing HIV prevalence drives the demand for HIV drugs:Rising HIV Incidence: The number of new HIV infections globally continues to be a significant concern. As the prevalence of HIV increases is the driving factor this market.
      • there is a greater need for effective treatment options is the driving factor this market.
      • which drives the demand for HIV drugs.Expanding High-Risk Populations: Certain population groups is the driving factor this market.
      • such as men who have sex with men (MSM) is the driving factor this market.
      • intravenous drug users is the driving factor this market.
      • and sex workers is the driving factor this market.
      • are at a higher risk of contracting HIV. The expansion of these high-risk populations due to various factors is the driving factor this market.
      • including urbanization and changing social behaviors is the driving factor this market.
      • contributes to the increasing prevalence of HIV and the subsequent demand for HIV drugs.Limited Access to Prevention Measures: In some regions is the driving factor this market.
      • limited access to preventive measures is the driving factor this market.
      • such as comprehensive sex education is the driving factor this market.
      • condoms is the driving factor this market.
      • clean needle exchange programs is the driving factor this market.
      • and pre-exposure prophylaxis (PrEP) is the driving factor this market.
      • can result in a higher rate of new HIV infections. As prevention measures are not universally available or accessible is the driving factor this market.
      • the demand for HIV drugs grows to address the existing infections.Aging HIV Population: With the development and availability of effective ART is the driving factor this market.
      • people living with HIV can manage the infection and live longer lives. Consequently is the driving factor this market.
      • the HIV population is aging is the driving factor this market.
      • leading to an increased demand for HIV drugs to address the long-term treatment needs of these individuals.The above-mentioned factors collectively contribute to the increasing prevalence of HIV and drive the demand for HIV drugs in the global market. The development of new and more effective antiretroviral therapies and other treatment innovations are expected to play a crucial role in meeting the growing demand for HIV drugs which will boost the growth of the global HIV drugs market during the forecast period. is the driving factor this market.

      The HIV Drugs market vendors should focus on grabbing business opportunities from the Offline segment as it accounted for the largest market share in the base year.